Enhanced Thiosuccinyl-Crosslinked Hemoglobin Conjugates for Improved Stability and Efficacy

This inventive concept presents a series of direct improvements and enhancements to thiosuccinyl-crosslinked hemoglobin conjugates, addressing limitations in stability, shelf life, immunogenicity, and manufacturing yield. The novel approaches include optimizing polyethylene glycol chain length, combining multiple water-soluble polymers, and utilizing biodegradable linkers, ultimately leading to more efficient and safer conjugates for repeated doses or prolonged exposure.

The original patent disclosed thiosuccinyl-crosslinked hemoglobin conjugates with polyethylene glycol (PEG) attachments, but these conjugates still faced challenges related to stability, immunogenicity, and manufacturing complexity. The present inventive concept addresses these limitations by introducing novel modifications to the PEG chain length, water-soluble polymer combinations, and linker designs, thereby enhancing the conjugates' overall performance and suitability for therapeutic applications.

The inventive concept comprises five key aspects: (1) modifying the PEG chain length to optimize its molecular weight between 5,000 to 20,000 Daltons, resulting in improved conjugate stability; (2) combining at least two water-soluble polymers with distinct molecular weights to enhance shelf life; (3) utilizing a portable infusion device with a built-in sensor to monitor the conjugate's concentration and automatically adjust the infusion rate; (4) covalently attaching the water-soluble polymer to the tetrameric hemoglobin via a novel, biodegradable linker to reduce immunogenicity; and (5) implementing a two-step crosslinking reaction to minimize hemoglobin denaturation and improve manufacturing yield. These innovations collectively contribute to the development of more efficient, safer, and more reliable thiosuccinyl-crosslinked hemoglobin conjugates.

The present inventive concept's novelty lies in the combination of optimized PEG chain length, multi-polymer stabilization, biodegradable linkers, and advanced manufacturing processes, which collectively provide a significant improvement over the original patent's disclosures. The inventive step is evident in the non-obvious application of these novel elements to address the specific limitations of thiosuccinyl-crosslinked hemoglobin conjugates.

Alternative embodiments of the inventive concept may include the use of different water-soluble polymers, such as polyalkylene glycol or polyvinylpyrrolidone, or the incorporation of additional stabilizing agents. Variations of the linker design, such as the use of cleavable or pH-sensitive linkers, could also be explored to further enhance the conjugates' performance.

The enhanced thiosuccinyl-crosslinked hemoglobin conjugates have significant commercial potential in the pharmaceutical industry, particularly in the development of therapeutics for anemia, cancer, and other diseases requiring repeated doses or prolonged exposure. The target market includes pharmaceutical companies, research institutions, and hospitals, with potential applications in both human and veterinary medicine.